Qualitative difference between the cytotoxic T lymphocyte responses to melanocyte antigens in melanoma and vitiligo

被引:24
作者
Palermo, B
Garbelli, S
Mantovani, S
Scoccia, E
Da Prada, GA
Bernabei, P
Avanzini, MA
Brazzelli, V
Borroni, G
Giachino, C
机构
[1] Univ Turin, Dept Clin & Biol Sci, I-10043 Orbassano, Italy
[2] IRCCS Maugeri Fdn, Expt Immunol Lab, Pavia, Italy
[3] IRCCS Maugeri Fdn, Div Surg, Pavia, Italy
[4] IRCCS Maugeri Fdn, Div Med Oncol, Pavia, Italy
[5] San Giovanni Battista Hosp, CERMS, Turin, Italy
[6] IRCCS Policlin San Matteo, Res Lab, Pavia, Italy
[7] Univ Pavia, Inst Dermatol, Dept Human & Hereditary Pathol, I-27100 Pavia, Italy
关键词
autoimmunity; Melan-A/MART-1; TCR affinity; TCR down-regulation; tumor immunity;
D O I
10.1002/eji.200535110
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Vitiligo is a skin disorder characterized by depigmented macules secondary to melanocyte loss. An unusual facet is its relation to melanoma: Cytotoxic T lymphocytes directed to melanocyte antigens are found in both conditions and imply a breakdown of tolerance, yet the resulting immune reaction is the opposite. The mechanisms at the basis of these opposite effects are not known. Here, we performed a direct comparison of whole melanocyte-specific T cell populations in the two diseases. We demonstrate that neither precursor frequencies of Melan-A/MART-1-specific T lymphocytes nor their status of activation differ significantly. However, by using a tetramer-based T cell receptor down-regulation assay, we documented a higher affinity of vitiligo T cells. We calculated that the peptide concentration required for 50% of maximal receptor down-regulation differed by 6.5-fold between the two diseases. Moreover, only vitiligo T cells were capable of efficient receptor down-regulation and IFN-gamma production in response to HLA-matched melanoma cells, suggesting that this difference in receptor affinity is physiologically relevant. The differences in receptor affinity and tumor reactivity were confirmed by analyzing Melan-A/MART-1-specific clones established from the two diseases. Our results suggest that the quality, and not the quantity, of the melanocyte-specific cytotoxic responses differs between the two pathologies.
引用
收藏
页码:3153 / 3162
页数:10
相关论文
共 39 条
[1]   Phenotypic analysis of antigen-specific T lymphocytes [J].
Altman, JD ;
Moss, PAH ;
Goulder, PJR ;
Barouch, DH ;
McHeyzerWilliams, MG ;
Bell, JI ;
McMichael, AJ ;
Davis, MM .
SCIENCE, 1996, 274 (5284) :94-96
[2]   Progression of autoimmune diabetes driven by avidity maturation of a T-cell population [J].
Amrani, A ;
Verdaguer, J ;
Serra, P ;
Tafuro, S ;
Tan, RS ;
Santamaria, P .
NATURE, 2000, 406 (6797) :739-742
[3]   An expanded peripheral T cell population to a cytotoxic T lymphocyte (CTL)-defined, melanocyte-specific antigen in metastatic melanoma patients impacts on generation of peptide-specific CTLs but does not overcome tumor escape from immune surveillance in metastatic lesions [J].
Anichini, A ;
Molla, A ;
Mortarini, R ;
Tragni, G ;
Bersani, I ;
Di Nicola, M ;
Gianni, AM ;
Pilotti, S ;
Dunbar, R ;
Cerundolo, V ;
Parmiani, G .
JOURNAL OF EXPERIMENTAL MEDICINE, 1999, 190 (05) :651-667
[4]   Tumor antigens [J].
Boon, T ;
Old, LJ .
CURRENT OPINION IN IMMUNOLOGY, 1997, 9 (05) :681-683
[5]   T cell affinity maturation by selective expansion during infection [J].
Busch, DH ;
Pamer, EG .
JOURNAL OF EXPERIMENTAL MEDICINE, 1999, 189 (04) :701-709
[6]   Human CD8 co-receptor is strictly involved in MHC-peptide tetramer-TCR binding and T cell activation [J].
Campanelli, R ;
Palermo, B ;
Garbelli, S ;
Mantovani, S ;
Lucchi, P ;
Necker, A ;
Lantelme, E ;
Giachino, C .
INTERNATIONAL IMMUNOLOGY, 2002, 14 (01) :39-44
[7]  
D'Souza S, 1998, INT J CANCER, V78, P699, DOI 10.1002/(SICI)1097-0215(19981209)78:6<699::AID-IJC6>3.0.CO
[8]  
2-U
[9]   Prevalent role of TCR α-chain in the selection of the preimmune repertoire specific for a human tumor-associated self-antigen [J].
Dietrich, PY ;
Le Gal, FA ;
Dutoit, V ;
Pittet, MJ ;
Trautman, L ;
Zippelius, A ;
Cognet, I ;
Widmer, V ;
Walker, PR ;
Michielin, O ;
Guillaume, P ;
Connerotte, T ;
Jotereau, F ;
Coulie, PG ;
Romero, P ;
Cerottini, JC ;
Bonneville, M ;
Valmori, D .
JOURNAL OF IMMUNOLOGY, 2003, 170 (10) :5103-5109
[10]   A shift in the phenotype of melan-A-specific CTL identifies melanoma patients with an active tumor-specific immune response [J].
Dunbar, PR ;
Smith, CL ;
Chao, D ;
Salio, M ;
Shepherd, D ;
Mirza, F ;
Lipp, M ;
Lanzavecchia, A ;
Sallusto, F ;
Evans, A ;
Russell-Jones, R ;
Harris, AL ;
Cerundolo, V .
JOURNAL OF IMMUNOLOGY, 2000, 165 (11) :6644-6652